Sumitomo Dainippon Pharma Annual Report 2017
9/102

Corporate GovernanceP.41Board Members and Executive OfficersP.49Shareholder DataP.99Financial SectionP.61Eleven-Year Summary of Selected Financial Data / Operating Results and Financial Condition /Business Risks / Consolidated Balance Sheets / Consolidated Statements of Income / Consolidated Statements of Changes in Net Assets / Consolidated Statements of Cash Flows /Notes to Consolidated Financial StatementsCSR ManagementP.51Our approach to CSR-based management / Labor Practices / Fair Operating Practices / Consumer Issues / Community Involvement and Development / EnvironmentP.35P.37P.39P.40Pharmaceutical Business: Japanese MarketPharmaceutical Business: North American MarketPharmaceutical Business: Chinese MarketRelated BusinessP.33MarketingP.31Corporate Regulatory Compliance & Quality AssuranceThe Sumitomo Dainippon Pharma Group’s active initiatives on issues, including development of a governance system, responses to environmental problems, and initiatives toward social problems have been highly evaluated. We have been selected for indices for socially responsible investment that include the FTSE4Good Index Series, the MSCI Global Sustainable Indexes, and the Morningstar Socially Responsible Investment Index. Please see p. 100 for related details. (As of July 2017)External Evaluations of Sumitomo Dainippon Pharma Group on Sustainability• FTSE4Good Index Series• FTSE Blossom Japan Index• MSCI Global Sustainability Indexes• MSCI Japan ESG Select Leaders Index• MSCI Japan Empowering Women Index (WIN)• Morningstar Socially Responsible Investment Index• SNAM Sustainability index08Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#9

このブックを見る